



**CLAIMS**


1. A process for the preparation of the compound of formula II



and pharmaceutically acceptable salts thereof which process comprises reaction of the compound of formula III or alternate salt thereof




and the compound of formula V




in a suitable solvent and at a suitable temperature under reductive conditions comprising hydrogen in the presence of a metal catalyst so as to give the compound of formula II followed by conversion to a pharmaceutically acceptable salt as required.

2. A process for the preparation of the compound of formula II



II


which process comprises reaction of the compound of formula XX



XX


or any other suitable alternate salt (or the neutral, parent amine) thereof with the compound of formula XIV

59



XIV


in a suitable solvent and in the presence of a base (not required when using the neutral, parent amine XX) to give the compound of formula XIII




XIII

followed by deprotection so as to give the compound of formula II.


### 3. A process for the preparation of the compound of formula II




and pharmaceutically acceptable salts thereof which process comprises reacting the compound of formula XVI




with the compound of formula XXVII



in a suitable solvent in the presence of a base and a source of iodide to give the compound of formula XXVI




which is then reduced in a suitable alcoholic solvent under transfer hydrogenation conditions and using a homochiral transition metal/ligand complex to give the compound of formula XXV




which is then deprotected in a suitable solvent in the presence of a metal catalyst for example palladium black so as to give the compound of formula II followed by conversion to a pharmaceutically acceptable salt as required.


#### 4. A process for the preparation of the compound of formula II




and pharmaceutically acceptable salts thereof which process comprises reaction of a compound of formula XXIII




in a suitable solvent, by the addition of t-butylvinyl ether; a metal catalyst or ligand / phase transfer catalyst / base combination to give a compound of formula XXVIII



which is then converted to a compound of formula V




via addition to a suitable acid which is then reacted with the compound of formula III




or any alternative salt thereof, in a suitable solvent under hydrogenation conditions in the presence of a metal catalyst or borane based reducing agent

so as to give the compound of formula II followed by conversion to a pharmaceutically acceptable salt as required


5. A process for the preparation of the compound of formula II




and pharmaceutically acceptable salts thereof which process comprises reaction of a compound of formula XX or alternate salt thereof



with the compound of formula XXIX




in a suitable solvent and in the presence of a base to give a compound of the compound of formula XIII




followed by deprotection to give a compound of formula II followed by conversion to a pharmaceutically acceptable salt as required

6. A process for the preparation of the compound of formula II and pharmaceutically acceptable salts thereof which process comprises reacting the compound of formula XXVII




with the compound of formula XIV

62




in a suitable solvent and base to give the compound of formula XXV




followed by deprotection, to give a compound of formula II and followed by conversion to a pharmaceutically acceptable salt as required.

7. A process for the preparation of the compound of formula II and pharmaceutically acceptable salts thereof which comprises reaction of the compound of formula III or any other suitable alternate salt thereof




and the compound of formula V




8. A novel intermediate compound as set out in Table 1 hereinbefore.

**CLAIMS**

1. A process for the preparation of the compound of formula II and pharmaceutically acceptable salts thereof which comprises reaction of the compound of formula III or any other suitable alternate salt thereof



and the compound of formula V



2. An intermediate compound of formula V

